請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89629
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙 | zh_TW |
dc.contributor.advisor | Hsiu-Hsi Chen | en |
dc.contributor.author | 吳張瑀 | zh_TW |
dc.contributor.author | Ariel Chang-Yu Wu | en |
dc.date.accessioned | 2023-09-13T16:08:44Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-13 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-03 | - |
dc.identifier.citation | Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, Muir BB, Prescott RJ, Smith A. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999 Jun 5;353(9168):1903-8.
Allgood PC, Warwick J, Warren RM, Day NE, Duffy SW. A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. Br J Cancer. 2008 Jan 15;98(1):206-9. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfússon B. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988 Oct 15;297(6654):943-8. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;(22):63-7. Bjurstam N, Björneld L, Warwick J, Sala E, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafström LO, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Säve-Söderbergh J, Wahlin T. The Gothenburg Breast Screening Trial. Cancer. 2003 May 15;97(10):2387-96. Chang RW, Jen GH, Lin KC, Cheng TC, Chuang SY, Pan SL, Chen TH, Yen AM. Evaluating the effectiveness of population-based breast cancer service screening: an analysis of parsimonious patient survival information with the time-varying Cox model. Int J Epidemiol. 2022 Dec 13;51(6):1910-1919. Choi E, Jun JK, Suh M, Jung KW, Park B, Lee K, Jung SY, Lee ES, Choi KS. Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality. NPJ Breast Cancer. 2021 Jun 28;7(1):83. Chen TH, Yen AM, Fann JC, Gordon P, Chen SL, Chiu SY, Hsu CY, Chang KJ, Lee WC, Yeoh KG, Saito H, Promthet S, Hamashima C, Maidin A, Robinson F, Zhao LZ. Clarifying the debate on population-based screening for breast cancer with mammography: A systematic review of randomized controlled trials on mammography with Bayesian meta-analysis and causal model. Medicine (Baltimore). 2017 Jan;96(3):e5684. Chen LS, Yen AM, Duffy SW, Tabar L, Lin WC, Chen HH. Computer-aided system of evaluation for population-based all-in-one service screening (CASE-PASS): from study design to outcome analysis with bias adjustment. Ann Epidemiol. 2010 Oct;20(10):786-96. Chen LS, Yen MF, Wu HM, Liao CS, Liou DM, Kuo HS, Chen TH. Predictive survival model with time-dependent prognostic factors: development of computer-aided SAS Macro program. J Eval Clin Pract. 2005 Apr;11(2):181-93. Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, Zhang B, Payne J, Doyle G, Ahmad R. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014 Oct 1;106(11):dju261. Dibden A, Offman J, Duffy SW, Gabe R. Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality. Cancers (Basel). 2020 Apr 15;12(4):976. Duffy SW, Nagtegaal ID, Wallis M et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008;168:98–104. Duffy SW, Tabar L, Fagerberg G, Gad A, Gröntoft O, South MC, Day NE. Breast screening, prognostic factors and survival--results from the Swedish two county study. Br J Cancer. 1991 Dec;64(6):1133-8. Frisell J, Eklund G, Hellström L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat. 1991 Mar;18(1):49-56. Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician. 2001 Feb 1;63(3):513-22. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;2013(6):CD001877. Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. J Natl Cancer Inst. 1986 Aug;77(2):317-20. Hsu C-Y, Hsu W-F, Yen AM-F, Chen H-H. Sampling-based Markov regression model for multistate disease progression: Applications to population-based cancer screening program. Statistical Methods in Medical Research. 2020;29(8):2198-2216. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012 Nov 17;380(9855):1778-86. Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ. 2010 Mar 23;340:c1241. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010 Sep 23;363(13):1203-10. Kawai M, Kuriyama S, Suzuki A, Nishino Y, Ishida T, Ohnuki K, Amari M, Tsuji I, Ohuchi N. Effect of screening mammography on breast cancer survival in comparison to other detection methods: a retrospective cohort study. Cancer Sci. 2009 Aug;100(8):1479-84. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ. 1992 Nov 15;147(10):1459-76. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ. 1992 Nov 15;147(10):1477-88. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014 Feb 11;348:g366. Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011. Br J Cancer. 2017 Mar 14;116(6):828-839. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006 Dec 9;368(9552):2053-60. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006 Dec 9;368(9552):2053-60. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1123-1132. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Feb 16;164(4):244-55. Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1479-88. Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E; Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19 Suppl 1:33-41. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002 Mar 16;359(9310):909-19. Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993 Apr 17;341(8851):973-8. Paci E, Ponti A, Zappa M et al. Early diagnosis, not differential treatment, explains better survival in service screening. Eur J Cancer 2005;41:2728–34 Richardson A. Screening and the number needed to treat. J Med Screen. 2001;8(3):125-7. Siu AL; U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Feb 16;164(4):279-96. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005; 97:1195–203. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am. 2004 Sep;42(5):793-806, v. Smith RA, Duffy SW, Tabár L. Breast cancer screening: the evolving evidence. Oncology (Williston Park). 2012 May;26(5):471-5, 479-81, 485-6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. Tabar L, Vitak B, Yen MF, Chen HH, Smith RA, Duffy SW. Number needed to screen: lives saved over 20 years of follow-up in mammographic screening. J Med Screen. 2004;11(3):126-9. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Gröntoft O, Ljungquist U, Lundström B, Månson JC, Eklund G, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829-32. Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995 May 15;75(10):2507-17. Tabar L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, Chiu SY, Chen SL, Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011 Sep;260(3):658-63. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003 Apr 26;361(9367):1405-10. Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019 Feb 15;125(4):515-523. Taiwan Cancer Registry Annual Report, 2020. Wu JC, Anttila A, Yen AM, Hakama M, Saarenmaa I, Sarkeala T, Malila N, Auvinen A, Chiu SY, Chen TH. Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Res Treat. 2010 Jun;121(3):671-8. Yen AM, Tsau HS, Fann JC, Chen SL, Chiu SY, Lee YC, Pan SL, Chiu HM, Kuo WH, Chang KJ, Wu YY, Chuang SL, Hsu CY, Chang DC, Koong SL, Wu CY, Chia SL, Chen MJ, Chen HH, Chiou ST. Population-Based Breast Cancer Screening With Risk-Based and Universal Mammography Screening Compared With Clinical Breast Examination: A Propensity Score Analysis of 1 429 890 Taiwanese Women. JAMA Oncol. 2016 Jul 1;2(7):915-21. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89629 | - |
dc.description.abstract | 背景:
傳統大數據分析進行大規模族群篩檢效益評估需處理非常大筆的資料,過程耗時且複雜。乳癌篩檢從早期的隨機分派臨床試驗使用意向治療分析法(intention-to-treat analysis)比較受邀篩檢者和未受邀篩檢者乳癌存活,到開始大規模族群篩檢後以觀察性世代研究比較受邀篩檢者和未受邀篩檢者或是參與篩檢與未參與篩檢者(per-protocol analysis)乳癌存活,都需使用大量篩檢資料。本研究旨在以乳癌個案的死亡日期創造排序統計量,進而採拔靴機器學習方法建立時間相依篩檢暴露史用以代表族群篩檢資料,以有效估計傳統大數據分析乳癌篩檢效益,並以電腦模擬巢狀病例對照抽樣研究設計組織性篩檢之不偏及有效應用之評估方法。 方法: 本論文先以前瞻性世代研究設計進行傳統大數據分析乳癌篩檢效益評估,使用台灣地區三個篩檢時期大規模族群乳癌篩檢資料以時間相依性Cox等比例風險模型(time-dependent Cox proportional hazard model)進行乳房攝影篩檢效益評估。接著以拔靴機器學習分析方法,利用死於乳癌的排序統計量(以死亡日期進行排序),重新定義時間相依的篩檢暴露史作為族群篩檢暴露狀態之分佈,應用時間相依性轉換模型(time-dependent switched design)校正截切偏差、前導期偏差及病程長短偏差。最後以電腦模擬巢狀病例對照研究設計,從死於乳癌個案(病例組)與設限個案(對照組)選取隨機樣本進行前述拔靴機器學習分析方法,並檢視不同病例組及對照組樣本數與比例之估計不偏性。 結果: 傳統大數據分析台灣大規模乳房攝影篩檢於降低乳癌死亡率之相對危險性為0.67(95% CI 0.62-0.72),顯示乳房攝影篩檢能降低33%乳癌死亡率;二期以上乳癌發生風險比為0.70(95% CI 0.62-0.78),乳房攝影篩檢能降低30%晚期乳癌發生率。拔靴機器學習分析乳癌個案存活資料估計大規模族群隨機分派臨床試驗意向治療分析法的乳癌死亡的風險比為0.65(95% CI 0.61-0.68),結果顯示乳癌篩檢能降低35%乳癌死亡率。兩研究乳癌篩檢於存活的效益相近。在電腦模擬巢狀病例對照研究顯示病例組與對照組抽樣樣本數達50%以上或是病例組與對照組抽樣佔比與原資料的比例越相近,抽樣估計值會有較佳的涵蓋比例和不偏性。 結論: 根據傳統大數據分析結合傾向分數分析,顯示台灣大規模族群乳房攝影篩檢能夠降低33%的乳癌死亡率。以拔靴機器學習分析乳癌個案所得到篩檢效益,篩檢能降低35%乳癌死亡率,拔靴法結合時間相依篩檢暴露校正可以對族群篩檢達到不偏估計。本研究進一步使用巢狀病例對照研究設計的電腦模擬,找到有效的抽樣方法。如此對未來進行族群大規模篩檢效益評估將可提供不偏及更有效率的應用。 | zh_TW |
dc.description.abstract | Background:
Conventional big data analysis for evaluation of population-based screening effectiveness requires to process large-scale screening data, which is time-consuming and complex. Breast cancer screening has evolved from randomized clinical trials comparing breast cancer survival between invited and non-invited participants (intention-to-treat analysis), to observational cohort studies comparing invited and non-invited participants or attended and non-attended participants (per-protocol analysis) after the start of population-based mass screening, all of which require a large-scale screening data. Our aim is to create a ranking statistic based on the date of death from breast cancer cases to establish a time-dependent screening exposure history using the bootstrap machine learning method, in order to estimate the effectiveness of large-scale population-based breast cancer screening. Also, we will use a computer-simulated nested case-control study design to evaluate a sampling method to estimate the effectiveness. Methods: The paper first conducted conventional big data analysis for breast cancer screening effectiveness using a prospective cohort study design and a time-dependent Cox proportional hazard model based on large-scale population-based screening data from three screening periods in Taiwan. The bootstrap machine learning method was then used to redefine the time-dependent screening exposure history based on a ranking statistic of deaths from breast cancer cases (sorted by date of death), and to correct for lead-time bias, length-biased sampling bias, and truncation bias using a time-dependent switched design. Finally, a computer-simulated nested case-control study design was used to randomly select samples from breast cancer cases (case group) and censored cases (control group) who died from other causes, and the aforementioned bootstrap machine learning method was applied to examine the unbiased estimates for different sample sizes and sampling fractions in the case and control groups. Results: Conventional big data analysis showed that the relative risk of breast cancer mortality reduction in Taiwan population-based breast cancer mammography screening was 0.67 (95% CI 0.62-0.72), indicating a 33% reduction in breast cancer mortality. The hazard ratio of stage II or higher breast cancer incidence was 0.70 (95% CI 0.62-0.78), indicating a 30% reduction in the incidence of late-stage breast cancer. Bootstrap machine learning analysis of survival data for breast cancer cases estimated the hazard ratio for breast cancer mortality using the intention-to-treat analysis method of population-based randomized clinical trials to be 0.65 (95% CI 0.61-0.68), showing a 35% reduction in breast cancer mortality in screening. Both studies showed similar effectiveness of breast cancer screening. A computer simulation study revealed that estimates had higher coverage rates and lower bias when the sample size of both the case and control groups exceeded 50%, or when the ratio of sampled cases in the case and control groups in the sample resembled that of the total cases. Conclusion: According to conventional big data analysis combined with propensity score analysis, population-based mammography screening in Taiwan resulted in a 33% reduction in breast cancer mortality. The bootstrap machine learning analysis of breast cancer cases showed that screening resulted in a 35% reduction in breast cancer mortality. This indicates that using bootstrapping with time-dependent switch design can achieve unbiased estimation of population screening. Furthermore, this study used computer simulations based on nested case-control study design to find effective sampling methods. Therefore, it can be inferred that our study designs have the potential to provide unbiased estimates of the effectiveness of population-based screening. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-13T16:08:44Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-13T16:08:44Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員審定書 1
致謝 2 中文摘要 3 Abstract 5 第一章 前言 12 第二章 文獻回顧 13 2.1 乳癌的流行病學和台灣篩檢計畫 13 2.2 乳癌篩檢效益–隨機分派臨床試驗 14 2.3 乳癌篩檢效益–觀察性研究 16 2.4 乳癌篩檢效益––時間相依篩檢暴露校正拔靴機器學習分析 20 2.5 減少一位女性乳癌死亡所需邀請篩檢的人數(Number Needed to Invite) 25 2.6 電腦模擬巢狀病例對照抽樣分析 27 第三章 材料與方法 36 3.1 研究架構 36 3.2 研究對象 38 3.3 統計方法 40 3.3.1 乳癌篩檢描述性分析 40 3.3.2 傳統大數據分析時間相依Cox等比例風險模型 41 3.3.3 傳統大數據分析傾向分數變項調整法 41 3.3.4時間相依篩檢暴露校正拔靴機器學習分析 42 3.3.5電腦模擬巢狀病例對照抽樣分析 46 第四章 結果 47 4.1 台灣大規模乳癌篩檢 47 4.2 傳統大數據分析乳癌篩檢效益 47 4.3 拔靴機器學習分析方法評估乳癌篩檢效益 48 4.4 電腦模擬巢狀病例對照抽樣分析 49 第五章 討論 59 5.1 傳統大數據分析臺灣大規模乳癌篩檢效益 59 5.2 拔靴機器學習分析方法評估乳癌篩檢效益 60 5.3 電腦模擬巢狀病例對照分析於不同樣本數下族群篩檢效益 62 第六章 結論 64 第七章 參考資料 65 | - |
dc.language.iso | zh_TW | - |
dc.title | 病例存活拔靴機器學習法有效估計傳統乳癌篩檢效益–台灣族群乳癌經驗 | zh_TW |
dc.title | Patient Survival Data for Efficient Estimation of Mammography Screening Effectiveness with Bootstrap-based Machine Learning Methods: Taiwan Population-based Screening | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 嚴明芳;莊紹源;陳祈玲 | zh_TW |
dc.contributor.oralexamcommittee | Ming-Fang Yen;Shao-Yuan Chuang;Chi-Ling Chen | en |
dc.subject.keyword | 乳癌篩檢,存活分析,時間相依性,前導期偏差,截切偏差,抽樣, | zh_TW |
dc.subject.keyword | breast cancer screening,survival analysis,time-dependent,lead time bias,truncation,sampling, | en |
dc.relation.page | 72 | - |
dc.identifier.doi | 10.6342/NTU202302679 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2023-08-04 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 2.15 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。